Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis

Neurology

Volumn 84, Issue 8, 2015, Pages 784-793

  Radue, Ernst Wilhelm ^a   Barkhof, Frederik ^b   Kappos, Ludwig ^a   Sprenger, Till ^a   Häring, Dieter A ^c   De Vera, Ana ^c   Von Rosenstiel, Philipp ^c   Bright, Jeremy R ^d   Francis, Gordon ^c   Cohen, Jeffrey A ^e  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NOVARTIS PHARMA AG   (Switzerland)

^d OXFORD PHARMAGENESIS LTD   (United Kingdom)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; GADOLINIUM; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

AGE DISTRIBUTION; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; BRAIN VOLUME LOSS; CONTRAST ENHANCEMENT; CORRELATION COEFFICIENT; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; EXPLORATORY RESEARCH; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL DISABILITY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; TUMOR VOLUME; ANALOGS AND DERIVATIVES; BRAIN; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; LONGITUDINAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN SIZE; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRENDS;

BRAIN; DOUBLE-BLIND METHOD; FEMALE; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; ORGAN SIZE; PROPYLENE GLYCOLS; SPHINGOSINE; TREATMENT OUTCOME;

EID: 84923675269     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001281     Document Type: Article

References (33)

1. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 2006;5:158-170
2. De Stefano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010;74:1868-1876
3. Zivadinov R, Bergsland N, Dolezal O, et al. Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years. Am J Neuroradiol 2013;34:1931-1939
4. Fox NC, Jenkins R, Leary SM, et al. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology 2000;54:807-812
5. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999;53:1698-1704
6. Fotenos AF, Mintun MA, Snyder AZ, Morris JC, Buckner RL. Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Arch Neurol 2008;65: 113-120
7. Jacobsen C, Hagemeier J, Myhr KM, et al. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. J Neurol Neurosurg Psychiatry 2014;85:1109-1115
8. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125:1676-1695
9. Zivadinov R, Bakshi R. Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging 2004;14:27S-35S
10. Fisher E, Rudick RA, Simon JH, et al. Eight-year followup study of brain atrophy in patients with MS. Neurology 2002;59:1412-1420
11. Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 2014;75: 43-49
12. Rudick RA, Fisher E. Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): yes. Mult Scler 2013;19:1003-1004
13. Filippi M, Rocca MA, Barkhof F, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 2012;11:349-360
14. Kappos L, Radue EW, O'Connor P, et al. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
15. Calabresi PA, Radue EW, Goodin D, et al. Efficacy and safety of fingolimod in patients with relapsing-remitting multiple sclerosis: results from the 24-month phase 3 double-blind, randomised, placebo-controlled study (FREEDOMS II). Lancet Neurol 2014;13:545-556
16. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415
17. Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS Study. Lancet Neurol 2011;10:520-529
18. Kappos L, Radue EW, O'Connor P, et al. Switching therapy to fingolimod improves clinical and MRI outcomes: subgroup analysis from the fingolimod phase III FREEDOMS extension (up to 4 years) study. Mult Scler 2013; 19(11 suppl):74-558. P619
19. Reder AT, Jeffery D, Goodin D, et al. Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Mult Scler 2013;19(11 suppl):74-558. P1092
20. International Conference on Harmonisation. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice. Available at: http://www.ich.org/ fileadmin/Public-Web-Site/ICH-Products/Guidelines/ Efficacy/E6/E6-R1-Guideline.pdf. Accessed January 17, 2014
21. WorldMedical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net/en/30publications/ 10policies/b3/index.html. Accessed January 17, 2014
22. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479-489
23. Barkhof F, de Jong R, Sfikas N, et al. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler 2014;20:1704-1713
24. Chard DT, Griffin CM, Parker GJ, Kapoor R, Thompson AJ, Miller DH. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 2002; 125:327-337
25. Roosendaal SD, Bendfeldt K, Vrenken H, et al. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler 2011;17:1098-1106
26. Sanfilipo MP, Benedict RH, Sharma J, Weinstock-Guttman B, Bakshi R. The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. Neuroimage 2005;26:1068-1077
27. De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003;60:1157-1162
28. Paolillo A, Piattella MC, Pantano P, et al. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA. J Neurol 2004;251:432-439
29. Chatterjee S, Hadi AS. Regression Analysis by Example, 4th ed. Hoboken, NJ: Wiley; 2006
30. Kitzler HH, Su J, Zeineh M, et al. Deficient MWF mapping in multiple sclerosis using 3D whole-brain multi-component relaxation MRI. Neuroimage 2012; 59:2670-2677
31. Rudick RA, Lee JC, Nakamura K, Fisher E. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci 2009;282: 106-111
32. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006;66:172-177
33. De Stefano N, Airas L, Grigoriadis N, et al. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 2014;28:147-156.